Vertigo News and Research RSS Feed - Vertigo News and Research

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. [More]
Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015. [More]
National survey shows that most women don't know risks or symptoms of stroke

National survey shows that most women don't know risks or symptoms of stroke

A national survey released today by The Ohio State University Wexner Medical Center shows that most women don't know the risks or symptoms females face when it comes to having a stroke. [More]
Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. [More]
23andMe announces publication of genome-wide association study of motion sickness

23andMe announces publication of genome-wide association study of motion sickness

23andMe, Inc., the leading personal genetics company, today announced the publication of the first ever genome-wide association study of motion sickness. [More]
Whole exome sequencing helps Mayo Clinic neurologist solve a medical mystery

Whole exome sequencing helps Mayo Clinic neurologist solve a medical mystery

Precision medicine is getting a jump-start from a new national initiative announced in President Obama's State of the Union message. One Georgia family has already experienced its benefits: genomic testing called whole exome sequencing helped Mayo Clinic neurologist Zbigniew Wszolek, M.D., solve a medical mystery that had left a boy with painful, jerking spasms that at times prevented him from walking or talking. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures. [More]
Now, women experiencing morning sickness can benefit from Diclegis drug

Now, women experiencing morning sickness can benefit from Diclegis drug

Up to 85 percent of pregnant women are affected by nausea and vomiting of pregnancy (NVP), more commonly known as morning sickness. [More]
Treatments that involve neck manipulation may be linked with strokes

Treatments that involve neck manipulation may be linked with strokes

Treatments that involve neck manipulation may be associated with strokes, although this association is not proven, according to an American Heart Association Scientific Statement written by lead author Dr. Jose Biller of Loyola University Medical Center and other stroke experts. [More]
People who suffer from MdDS now have chance for full recovery by new treatment

People who suffer from MdDS now have chance for full recovery by new treatment

People who suffer from a rare illness, the Mal de Debarquement Syndrome (MdDS), now have a chance for full recovery thanks to treatment developed by researchers at the Icahn School of Medicine at Mount Sinai. [More]
Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford Health System has launched a clinical trial to investigate a new drug for the treatment of tinnitus, a chronic ringing of the head or ears that affects more than 600 million people worldwide. [More]
Neutra prepares new technology to make cannabis reliable cash crop in desert

Neutra prepares new technology to make cannabis reliable cash crop in desert

Neutra Corp. is preparing new technology for the marketplace designed to help make cannabis a reliable cash crop—even in the desert. [More]
Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones. [More]
Highlights from April 2014 issue of Mayo Clinic Health Letter

Highlights from April 2014 issue of Mayo Clinic Health Letter

Here are highlights from the April issue of Mayo Clinic Health Letter. [More]
Study sheds light on factors that lead to development of rare condition affecting inner ear

Study sheds light on factors that lead to development of rare condition affecting inner ear

A new study has shed light on the factors likely to lead to the development of a rare condition affecting the inner ear. [More]

Neutra prepares to roll out new game-changing technology in indoor horticulture industry

As Neutra Corp. (OTCBB: NTRR) and its joint venture partner prepare to roll out a new, game-changing technology in the indoor horticulture industry, the company announced today that work has already begun on new, customizable solutions for growing operations with uncommon requirements. [More]
Neutra seeks new breakthroughs in greenhouse cultivation to develop and market around globe

Neutra seeks new breakthroughs in greenhouse cultivation to develop and market around globe

In the company's quest to introduce new technology on the cutting edge of the indoor horticulture industry, Neutra Corp. (OTCBB: NTRR) is seeking out new breakthroughs in greenhouse cultivation to develop and market around the globe. [More]
New clinic that focuses on diagnosis and treatment for vertigo launched in Mumbai

New clinic that focuses on diagnosis and treatment for vertigo launched in Mumbai

In a first, a city hospital has launched a clinic dedicated to vertigo. Dr Rajeev Boudhankar, vice-president, Kohinoor Hospital, said, "We observed that vertigo is a highly under-diagnosed ailment and patients run from post to pillar looking for effective treatment. [More]
Advertisement
Advertisement